Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Accumulated Expenses (2018 - 2025)

Historic Accumulated Expenses for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to $3.2 million.

  • Precision Biosciences' Accumulated Expenses fell 1211.02% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 1211.02%. This contributed to the annual value of $5.2 million for FY2024, which is 409.8% up from last year.
  • Per Precision Biosciences' latest filing, its Accumulated Expenses stood at $3.2 million for Q3 2025, which was down 1211.02% from $2.4 million recorded in Q2 2025.
  • Over the past 5 years, Precision Biosciences' Accumulated Expenses peaked at $6.8 million during Q4 2021, and registered a low of $1.2 million during Q1 2024.
  • For the 5-year period, Precision Biosciences' Accumulated Expenses averaged around $3.6 million, with its median value being $3.6 million (2024).
  • In the last 5 years, Precision Biosciences' Accumulated Expenses skyrocketed by 1974.18% in 2022 and then plummeted by 3804.69% in 2023.
  • Precision Biosciences' Accumulated Expenses (Quarter) stood at $6.8 million in 2021, then fell by 24.55% to $5.1 million in 2022, then fell by 2.47% to $5.0 million in 2023, then grew by 4.1% to $5.2 million in 2024, then crashed by 39.08% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $2.4 million for Q2 2025, and $1.3 million during Q1 2025.